KeyCorp price target raised to $17 from $16 at Argus

Argus analyst Stephen Biggar raised the firm’s price target on KeyCorp to $17 from $16 and keeps a Buy rating on the shares after its Q2 results. The company’s lending balances have generally improved, and KeyCorp has mostly seen greater utilization of commercial loans and benefits from the launch of Laurel Road for Doctors – a national digital bank that offers savings accounts, credit cards, and other products for healthcare professionals, the analyst tells investors in a research note.